EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias

Tomoki Iemura, Toshio Kitawaki, Ryota Maeda, Takaya Mitsuyoshi, Kayoko Nagata, Hiroyuki Yamazaki, Kotaro Shirakawa, Naohiro Kobayashi, Takashi Nagata, Akihiro Imura, Akifumi Takaori-Kondo

Journal for ImmunoTherapy of Cancer · 2026-08 · 14 (8) · e014419

DOI: 10.1136/jitc-2025-014419 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 03.08.2026. Verfasst von Tomoki Iemura und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Receptors, OX40, Single-Domain Antibodies, Epitopes. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ZE Research Program, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Conventional antibody discovery approaches that do not account for enrichment-driven biases, such as epitope immunogenicity, PCR amplification bias, or protein expression efficiency, may result in under-representation of rare yet functionally relevant clones, necessitating labor-intensive in vitro screening to identify agonistic antibodies among a large number of dominant clones. Thus, efficient screening methods for agonistic antibodies are urgently needed. OX40 is a promising target for cancer immunotherapy due to its role in enhancing T-cell activation and survival. However, effective anti-OX40 agonistic antibodies have not yet been developed.

Methods

We developed a novel screening strategy that involves the selection of nanobody clone pools enriched by biopanning against gp34-engaged and non-engaged OX40-expressing cells, next-generation sequencing, and computational clustering and subtraction analysis to identify clones recognizing the ligand-receptor interface. Representative nanobody clones underwent in vitro validation, including epitope mapping, binding affinity measurements, and functional assessments. Furthermore, we engineered the selected nanobody to enhance its in vivo efficacy. We also performed structural analysis of the nanobody-OX40 complex.

Results

Our epitope-directed approach efficiently identified nanobody clones recognizing functionally relevant epitopes distinct from dominant immunogenic regions. Notably, clone Nb479 demonstrated robust agonistic activity, closely mimicking the natural ligand gp34 with extensive OX40-binding interactions. Trimerization of Nb479 facilitated potent OX40 activation without the need for a cross-linking scaffold. Conjugation of the Nb479 trimer with an anti-serum albumin nanobody exhibited significantly improved pharmacokinetics in vivo and enhanced antitumor activity in a mouse model treated with CD19 chimeric antigen receptor T cells.

Conclusion

This study presents an innovative epitope-directed approach that greatly accelerates the discovery of functionally potent agonistic nanobodies by effectively circumventing enrichment-driven epitope bias. Our approach and engineered multivalent anti-OX40 nanobody offer a powerful platform to advance immunotherapeutic strategies for cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, OX40Single-Domain AntibodiesEpitopesAnimalsHumansMiceEpitope MappingFemaleImmunotherapy

Stichwörter der Autor:innen

AntibodyChimeric antigen receptor - CARImmunotherapyT cellco-stimulatory molecules

Substanzen

Receptors, OX40Single-Domain AntibodiesEpitopes

Autor:innen und Institutionen

  • Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan kitawaki@kuhp.kyoto-u.ac.jp.
  • COGNANO Inc, Kyoto, Japan.
  • RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan.
  • Institute of Advanced Energy, Graduate School of Energy Science, Integrated Research Center for Carbon Negative Science, Kyoto University, Uji, Japan.

Förderung

  • ZE Research Program
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science

Zitieren

APA

Iemura, T., Kitawaki, T., Maeda, R., Mitsuyoshi, T., Nagata, K., Yamazaki, H., Shirakawa, K., Kobayashi, N., Nagata, T., Imura, A., & Takaori-Kondo, A. (2026). Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias. Journal for ImmunoTherapy of Cancer, 14(8), e014419. https://doi.org/10.1136/jitc-2025-014419

Vancouver

Iemura T, Kitawaki T, Maeda R, Mitsuyoshi T, Nagata K, Yamazaki H, et al. Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias. Journal for ImmunoTherapy of Cancer. 2026;14(8):e014419. doi:10.1136/jitc-2025-014419

BibTeX
@article{Iemura2026,
  author = {Iemura, Tomoki and Kitawaki, Toshio and Maeda, Ryota and Mitsuyoshi, Takaya and Nagata, Kayoko and Yamazaki, Hiroyuki and Shirakawa, Kotaro and Kobayashi, Naohiro and Nagata, Takashi and Imura, Akihiro and Takaori-Kondo, Akifumi},
  title = {Efficient discovery of an agonistic anti-OX40 nanobody by epitope-directed approach to address enrichment-driven epitope bias},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {8},
  pages = {e014419},
  doi = {10.1136/jitc-2025-014419}
}
Kostenlos starten →